KOSDAQFood & Beverage368970

OSP

₩1,706▼ 4.05%2026-11-18 close
Market Cap
₩19.2B
Turnover
₩2,351,284
Volume
1.4K
Shares out.
11.2M
PER
—
PBR
0.5×
EPS
-₩310
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

OSP: Operating Profit Positive, Net Losses Still Open

OSP recorded operating profit in each quarter from Q1 to Q3 2026 as its own-brand share grew, but net losses attributable to controlling shareholders and sales declines since 2024 remain open issues.

  1. 1

    Annual sales peaked at KRW 35.2 billion in 2023, then fell to KRW 30.3 billion in 2024 and KRW 25.4 billion in 2025.

  2. 2

    Operating profit was KRW 454 million in Q1 2026, KRW 474 million in Q2 and KRW 142 million in Q3, while the Q3 net loss attributable to controlling shareholders was KRW 1.06 billion.

  3. 3

    The net loss attributable to controlling shareholders over the last four quarters totaled KRW 2.68 billion.

  4. 4

    The business shift centers on own-brand exports and new overseas channels in Chile, Kazakhstan and North America.

  5. 5

    In 2026 the company carried out a third-party rights issue, a bonus issue and a share buyback, and later disclosed that its administrative-issue designation had been lifted.

02

Business structure

OSP is a pet food company that makes dry and functional animal feed. It began in 2004 as a paper packaging maker, moved into pet feed compounding in 2011, and listed on KOSDAQ in 2022. The business has two pillars: ODM production for other brands and sales of its own-brand (PB) products.

In 2022 the sales mix was 90% ODM products, 8% PB products and 2% other, but a first-half 2026 news report said the PB share had risen to about 36%. Its flagship PB line is Indigo, including the Indigo Pet Origin range, which is built on organic ingredients certified under USDA-NOP and Korean organic standards.

In January 2023 OSP acquired a stake in a Korean maker of semi-moist feed and treats, consolidated it as a subsidiary, and that consolidation explains much of the 2023 sales jump.

Existing ODM clients include Pulmuone Corporate and other long-standing customers, and the company cited expanded cooperation with them as a growth driver. Overseas sales were KRW 1.742 billion in 2025, up 26.3% from the prior year, and accounted for 16.4% of sales.

Market conditions are described as weaker domestic consumption and rising competition in the pet industry, and the 2025 decline was attributed to lower ODM demand and tougher competition. The parent company's animal medicine and pharmaceutical R&D capabilities are being applied to plan prescription feed. The company had 36 employees as of the end of September 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.4B-₩500M−7.6%
2025Q4₩6.6B₩88,0960.0%
2026Q1₩7.2B₩500M6.3%
2026Q2₩6.9B₩500M6.8%
2026Q3₩6.3B₩100M2.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16.8B₩1.1B₩1.1B6.5%3.2%8.0%
2023₩35.2B₩2B-₩400M5.8%−1.1%61.1%
2024₩30.3B-₩58,743,717₩2.4B−0.2%6.5%47.7%
2025₩25.4B-₩1.3B-₩3.3B−5.0%−10.4%50.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual sales peaked at KRW 35.2 billion in 2023 and then declined in both 2024 and 2025. Sales rose from KRW 16.8 billion in 2022 to KRW 35.2 billion in 2023, an increase of 109.3%, which the company attributed largely to the consolidation of its subsidiary in January 2023.

Sales fell 13.8% to KRW 30.3 billion in 2024 and 16.2% to KRW 25.4 billion in 2025, and a 2025 third-quarter cumulative disclosure attributed weaker ODM sales to falling market demand and intensifying competition.

Operating profit was KRW 1.09 billion in 2022 and KRW 2.04 billion in 2023, an 86.9% increase, before the company swung to an operating loss of KRW 58.74 million in 2024 and a wider loss of KRW 1.28 billion in 2025. The operating margin slid from 6.5% in 2022 to 5.8% in 2023, -0.2% in 2024 and -5.0% in 2025.

In 2024 the company posted an operating loss yet a net profit attributable to controlling shareholders of KRW 2.35 billion, so operating and bottom-line results moved in opposite directions.

In 2025 that figure returned to a loss of KRW 3.29 billion, and the total net loss including non-controlling interests was KRW 3.28 billion. Operating cash flow stayed positive at KRW 2.52 billion in 2025, and the debt ratio moved from 61.1% in 2023 to 47.7% in 2024 and 50.7% in 2025.

At the end of 2025 total equity was KRW 43.6 billion, of which KRW 31.7 billion belonged to controlling shareholders, and total liabilities were KRW 22.1 billion.

Quarterly sales peaked at KRW 7.2 billion in Q1 2026, then slipped to KRW 6.95 billion in Q2 and KRW 6.33 billion in Q3, which was down 1.9% from a year earlier.

Quarterly operating profit moved from an operating loss of KRW 491 million in Q3 2025 to KRW 0.09 million in Q4 2025, then KRW 454 million in Q1 2026, KRW 474 million in Q2 and KRW 142 million in Q3, and the company cited a roughly 22% rise in PB export sales as a factor in the Q1 turnaround.

Net income attributable to controlling shareholders was a loss of KRW 674 million in Q3 2025, a loss of KRW 1.37 billion in Q4 2025, a loss of KRW 456 million in Q1 2026, a profit of KRW 211 million in Q2 2026 and a loss of KRW 1.06 billion in Q3 2026, and the four-quarter total of such losses is KRW 2.68 billion.

The composition of non-operating income and expenses, which explains the gap between positive Q3 2026 operating profit and the controlling-shareholder net loss, is the item to check in the next annual report.

05

Industry analysis

The pet food market is under two pressures at once: weaker domestic consumption and intensifying competition within the pet industry. An April 2026 news report read OSP's 2025 sales decline as a reflection of these two factors.

ODM demand fell in the cumulative period through Q3 2025 on lower market demand and tougher competition, but in the first half of 2026 expanded cooperation with existing clients including Pulmuone Corporate and new supply contracts were cited as growth drivers.

Overseas, Chile was introduced as a South American pet market of roughly KRW 2 trillion, and the company plans to use Chile as a base for entering the Americas. Kazakhstan was described as the largest economy in Central Asia and a logistics hub with access to the wider CIS region.

The company said the Korea-Canada pet food quarantine agreement reached in 2026 widened its access to North America.

OSP is seeking differentiation through functional feed that combines organic ingredients with pharmaceutical and biotech technology from its parent, and it had 36 employees as of the end of September 2026.

Under the sector classification, OSP is listed in the KOSDAQ food and tobacco category, and the government's planned increase in the KOSDAQ market-capitalization threshold to KRW 20 billion in the second half of 2026 and KRW 30 billion in 2027 changes listing-maintenance conditions independently of industry demand.

06

Outlook

The main target the company has set is an operating profit turnaround for full-year 2026, and operating profit was positive in each of Q1 to Q3 2026. Whether full-year 2026 operating profit is positive will be confirmed in the 2026 annual report, which includes Q4 results.

In its growth plan announced in August 2026, the company said it aims to lift the PB share of exports to more than 70% within three years. The core strategy is to move from a B2B-centered structure toward higher-margin B2C sales in order to raise the operating margin.

The company said overseas sales are expected to reach the low 20% range of total sales in 2026 and targets 40% within three years. It also said that shifting marketing toward channels with higher purchase conversion is expected to improve profitability by about 7% to 8% a year.

Plans for the second half of 2026 include building a Chile-only online store, entering the largest online platform in South America and listing in Costco Taiwan.

The company plans M&A and equity investments in small and mid-sized technology firms in biotech, defense, AI and energy within 2026, but the targets and deal sizes have not been disclosed. Shareholder returns are framed around continued share buybacks and open-market purchases by new management.

Prescription feed is planned using the parent company's animal medicine and pharmaceutical research capabilities, and no launch timing has been disclosed.

07

Valuation

PER
—
PBR
0.5×
ROE
-8.3%
EPS
-₩310
BPS
₩4,353
Dividend per share
₩0

The price-to-book ratio is below 1x, and the company itself described its low price-to-book level as an issue to address through earnings recovery and a fair valuation of its corporate value.

Because the last four quarters have all been net losses attributable to controlling shareholders, the price-to-earnings ratio is not calculated.

At the end of 2025 total equity was KRW 43.6 billion, of which KRW 31.7 billion belonged to controlling shareholders, so net asset value is larger than the market capitalization. The market capitalization is below the KRW 30 billion threshold the government plans to apply in 2027.

The cash dividend yield is low, and shareholder returns have centered on treasury share cancellation, buybacks and a bonus issue. Over several years, controlling-shareholder net income moved into profit in 2024 and back to a loss in 2025, which makes earnings-based multiples hard to interpret.

Operating profit has been positive from Q1 to Q3 2026, so whether an earnings-based multiple can be calculated again depends on how far the controlling-shareholder net loss narrows.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Shift toward own-brand products

The company said PB export sales of its Indigo brand rose about 22% year on year in Q1 2026. That increase was cited as a driver of the first-quarter operating profit turnaround, and operating profit stayed positive in Q3 2026. The company plans to lift the PB share of exports to more than 70% within three years. Its argument is that moving from B2B toward higher-margin B2C sales will improve the operating margin.

Expanding overseas channels

OSP made its first shipments to Kazakhstan and Chile in April 2026 and says Chile will serve as a base for the Americas. It took part in SuperZoo 2026 in the United States in August 2026 and held supply talks with local buyers.

The company said the Korea-Canada pet food quarantine agreement widened its access to North America. Overseas sales rose 26.3% in 2025 to a 16.4% share of sales, and the company expects that share to reach the low 20% range in 2026.

Capital raising and shareholder returns

OSP retired about 210,000 treasury shares in March 2026 and carried out a bonus issue of 0.5 new shares per share held in June. It approved a share buyback worth KRW 2 billion in July.

To meet listing-maintenance criteria, it resolved a KRW 5.6 billion third-party rights issue, with the largest shareholder taking up KRW 1 billion. The company said in September 2026 that it had received notice that its administrative-issue designation was lifted.

09

Bear factors

Two years of falling sales and weaker domestic demand

Sales peaked at KRW 35.2 billion in 2023 and fell to KRW 30.3 billion in 2024, a 13.8% decline, and to KRW 25.4 billion in 2025, a 16.2% decline. Weaker domestic consumption and tougher competition in the pet industry were cited for the 2025 drop.

Q3 2026 sales of KRW 6.33 billion were 1.9% lower than a year earlier, and sales have declined in each of the two quarters since the Q1 2026 peak.

Continued net losses for controlling shareholders

Net loss attributable to controlling shareholders was KRW 3.29 billion in 2025, a swing back to loss after the 2024 profit.

In Q3 2026 operating profit was KRW 142 million, yet the net loss attributable to controlling shareholders widened to KRW 1.06 billion, so operating profit did not carry through to the bottom line. The composition of non-operating income and expenses is the item to check in the next annual report.

Higher share count and a rising market-cap threshold

Bonus and third-party rights issues have increased the share count, and the 1,456,709 new shares listed under the third-party allotment carry a mandatory holding period through July 23, 2027. The new shares were priced at KRW 1,571.

The government plans to raise the KOSDAQ market-capitalization threshold to KRW 30 billion in 2027, and the current market capitalization is below that level. The company said the administrative designation reflected a revision of the listing system rather than business weakness.

10

Risk factors

Market demand and competition

Weaker domestic consumption and rising competition in the pet industry were cited for the 2025 sales decline. Lower demand from ODM clients could affect both volumes and pricing terms. Reporting also said higher marketing costs and online channel fees for the Indigo brand weighed on profitability through 2025.

Listing maintenance and share count

The administrative-issue designation was lifted and disclosed in September 2026, but the government plans to raise the KOSDAQ market-capitalization threshold to KRW 30 billion in 2027.

Bonus shares and third-party allotment shares have increased the share count, which makes comparison with past per-share figures difficult. If the market capitalization moves near the threshold, listing-requirement compliance could again become an issue.

Execution of overseas expansion

First shipments to Chile and Kazakhstan and participation in SuperZoo have started, but overseas sales were KRW 1.742 billion in 2025, only 16.4% of the total. Targets of more than 70% PB export share and 40% overseas sales share within three years depend on execution speed. No launch timing has been disclosed for prescription feed developed with the parent's research capabilities.

11

What to watch next

  1. November 16, 2026

    Record date for voting rights at the extraordinary general meeting. Agenda details are to be fixed by the board and re-disclosed.

  2. December 14, 2026

    Scheduled extraordinary general meeting at 10:00 a.m. at the head office in Nonsan, South Chungcheong. The re-disclosed agenda and voting results are the next checkpoints.

  3. By end of 2026 (stated plan)

    Whether the targets and sizes of planned M&A and equity investments are disclosed, and whether the Chile-only online store and the Costco Taiwan listing begin.

  4. Around late March 2027

    Filing of the 2026 annual report. Full-year operating profit including Q4, the composition of non-operating items and the overseas sales share are the checkpoints.

  5. July 23, 2027

    End of the mandatory holding period for the 1,456,709 third-party allotment shares. It coincides with the 2027 increase in the market-capitalization threshold to KRW 30 billion.

12

Overall view

OSP's annual sales peaked at KRW 35.2 billion in 2023 and declined in 2024 and 2025, and in 2025 its operating loss widened and net loss attributable to controlling shareholders returned. Operating profit was positive in each quarter from Q1 to Q3 2026, supported by a higher PB share and rising exports.

However, the Q3 2026 net loss attributable to controlling shareholders was KRW 1.06 billion and the four-quarter total is KRW 2.68 billion, so whether operating profit carries through to net income remains the open issue.

As of the end of 2025, total equity was KRW 43.6 billion, the debt ratio was 50.7%, total liabilities were KRW 22.1 billion, and operating cash flow was positive at KRW 2.52 billion.

Capital raising and shareholder returns have run in parallel, and the administrative-issue designation has been lifted, but the government's planned increase in the market-capitalization threshold and the holding period on new shares remain points to monitor for listing status and share count.

Overseas, OSP made its first shipments to Chile and Kazakhstan and attended a U.S. trade show, and the company set targets of more than 70% PB export share and 40% overseas sales share within three years. On valuation, the price-to-book ratio is below 1x, and the price-to-earnings ratio is not calculated.

The next checkpoints are the agenda of the December 14, 2026 extraordinary general meeting, the full-year operating profit and non-operating items in the 2026 annual report, and changes in the overseas sales share.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. markets.hankyung.com
  4. ssl.pstatic.net
  5. biotimes.co.kr
  6. calculator.io.kr
  7. kr.tradingview.com
  8. news.nate.com
  9. newconomy.co.kr
  10. newspim.com
  11. newspim.com
  12. m.news.nate.com
  13. newspim.com
  14. newspim.com
  15. digitaltoday.co.kr
  16. newspim.com
  17. cstimes.com
  18. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis